共 50 条
Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines
被引:7
|作者:
Henson, Brianna
[1
]
Hollingsworth, Hanna
[2
]
Nevois, Erika
[3
]
Herndon, Chris
[4
]
机构:
[1] Wake Forest Baptist Hlth Brenner Childrens Hosp, Winston Salem, NC USA
[2] Parkland Hlth & Hosp Syst, Dallas, TX USA
[3] CVS Pharm, Springfield, IL USA
[4] Southern Illinois Univ Edwardsville, Sch Pharm, 200 Univ Pk Dr, Edwardsville, IL 62026 USA
关键词:
CGRP;
migraine;
calcitonin gene-related peptide;
erenumab;
galcanezumab;
fremanezumab;
DOUBLE-BLIND;
EPISODIC MIGRAINE;
RECEPTOR ANTAGONISTS;
PREVENTIVE TREATMENT;
EFFICACY;
SAFETY;
ANTIBODY;
PHASE-2;
TRIAL;
D O I:
10.1080/15360288.2019.1690616
中图分类号:
R614 [麻醉学];
学科分类号:
100217 ;
摘要:
Migraine is highly prevalent and associated with a large socio-economic burden in the United States. Current preventive medications have variable efficacy and their use is often limited by intolerable side effects. Calcitonin gene-related peptide (CGRP) has been identified as an integral part of migraine pathophysiology. There are currently seven CGRP antagonists under investigation, all of which are undergoing or have completed phase 3 clinical trials. Three of the investigated CGRP antagonists are approved for use within and outside of the United States. The trials have resulted in positive efficacy and safety data. The purpose of this review is to evaluate the seven CGRP antagonists and their future place in therapy.
引用
收藏
页码:22 / 31
页数:10
相关论文